Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 68 Suppl 8, 35-41

Revisiting Monoamine Oxidase Inhibitors

  • PMID: 17640156

Revisiting Monoamine Oxidase Inhibitors

K Ranga Krishnan. J Clin Psychiatry.


Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms


LinkOut - more resources